Palo Protocol

BPC-157 + KPV

Recovery & Gut

500 mcg / 500 mcg · 60 capsules

The gut-focused pairing. Both compounds are preclinical and both require a prescriber relationship we are still building.

Not available for purchase

What we know

Mechanism: Pairs BPC-157 with KPV, the C-terminal tripeptide of alpha-MSH, studied for anti-inflammatory activity in the gut lining.
Evidence state: Preclinical, with mechanistic interest in inflammatory bowel models.
Regulatory note: BPC-157 is on the FDA 503A Category 2 list. Prescriber pathway only.

Disclaimer

This product is not available for purchase. It has not been evaluated by the FDA and is not intended to diagnose, treat, cure or prevent any disease. Nothing on this page is medical advice. Palo lists this compound for transparency about our supply partnerships; any future availability would run through a licensed prescriber and a compounding pharmacy, not through this website.